Improvement of Arterial Stiffness by Reducing Oxidative Stress Damage in Elderly Hypertensive Patients After 6Months of Atorvastatin Therapy

Journal of Clinical Hypertension

Volumn 14, Issue 4, 2012, Pages 245-249

  Wang, Junhong ^a   Xu, Jian ^a   Zhou, Chuanwei ^a   Zhang, Ying ^a   Xu, Di ^a   Guo, Yan ^a   Yang, Zhijian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ATORVASTATIN; C REACTIVE PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTICHOLESTEREMIC AGENTS; ARTERIES; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; PYRROLES; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC;

EID: 84862784420     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00600.x     Document Type: Article

References (26)

1. Vaitkevicius PV, Fleg JL, Engel JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation. 1993;88(4 Pt 1):1456-1462.
2. Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension. 2009;54:763-768.
3. Dolan E, Thijs L, Li Y, et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension. 2006;47:365-370.
4. Ghiadoni L, Bruno RM, Stea F, et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep. 2009;11:190-196.
5. Maldonado J, Pereira T, Polonia J, et al. Arterial stiffness predicts cardiovascular outcome in a low-to-moderate cardiovascular risk population: the EDIVA (Estudo de DIstensibilidade VAscular) project. J Hypertens. 2011;29:669-675.
6. Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol. 2007;34:647-651.
7. Semba RD, Najjar SS, Sun K, et al. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2009;22:74-79.
8. Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens. 2010;23:1183-1189.
9. Duprez DA. Arterial stiffness and endothelial function: key players in vascular health. Hypertension. 2010;55:612-613.
10. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932-943.
11. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health and Risk Manag. 2009;5:353-360.
12. Kaiser T, Heise T, Nosek L, et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24:1397-1403.
13. Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des. 2009;15:290-303.
14. Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis. 2007;49:776-785.
15. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010;8:638-644.
16. Mizuguchi Y, Oishi Y, Miyoshi H, et al. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J. 2008;72:538-544.
17. Ahmed N, Argirov OK, Minhas HS, et al. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl) lysine-modified albumin. Biochem J. 2002;364(Pt 1):1-14.
18. Kishi T, Hirooka Y, Konno S, Sunagawa K. Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2010;55:184-190.
19. Umeji K, Umemoto S, Itoh S, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol. 2006;291:H2522-H2532.
20. Ichihara A, Hayashi M, Koura Y, et al. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19:103-109.
21. Safar ME, London GM. Therapeutic studies and arterial stiffness in hypertension: recommendations of the European Society of Hypertension. The Clinical Committee of Arterial Structure and Function. Working Group on Vascular Structure and Function of the European Society of Hypertensions. J Hypertens. 2000;18:1527-1535.
22. Kotsis V, Stabouli S, Karafillis I, et al. Arterial stiffness and 24h ambulatory blood pressure monitoring in young healthy volunteers: the Early Vascular Ageing Aristotle University Thessaloniki Study (EVA-ARIS Study). Atherosclerosis. 2011;19:194-199.
23. Shapiro BP, Owan TE, Mohammed SF, et al. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation. 2008;118:1002-1010.
24. Bonomini F, Tengattini S, Fabiano A, et al. Atherosclerosis and oxidative stress. Histol Histopathol. 2008;23:381-390.
25. Didion SP, Ryan MJ, Didion LA, et al. Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice. Circ Res. 2002;91:938-944.
26. Groleau J, Dussault S, Turgeon J, et al. Accelerated vascular aging in CuZnSOD-deficient mice: impact on EPC function and reparative neovascularization. PLoS One. 2011;6:e23308.